Vicriviroc - Top 10 Phase III Failures

The drug: Vicriviroc
The disease: HIV
The company: Merck

Back when Schering-Plough was pushing vicriviroc up the pipeline, CEO Fred Hassan boldly predicted that the HIV therapy was headed for a regulatory filing in early 2010 and would go on to reap as much as $750 million in 2013. And Merck was just as upbeat about its chances when the drug giant bought out Schering-Plough.

So much for bold predictions in the development business. In early 2010 Merck researchers explained that two Phase III trials of vicriviroc, a CCR5 co-receptor antagonist designed to block the virus from penetrating cells, failed to hit the primary endpoint among patients taking a drug cocktail.

A few months later, when the drug failed a study involving treatment-naïve patients, Merck killed the development program.

Vicriviroc - Top 10 Phase III Failures

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.